There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech…
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate sodum (PPS) (now known as Zilosul) to market. It is…